TRACON Pharmaceuticals (NASDAQ:TCON) jumps 12.88% after the company highlights data at the ASCO Virtual Scientific Program
The company presented new positive results on Envafolimab and Opdivo/Yervoy combination therapy.
Previously: All eyes on ASCO (May 29)
#ASCO2020
https://seekingalpha.com/news/3578635-tracon-pops-after-asco-poster
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.